All News
Filter News
Found 925 articles
-
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
8/28/2023
The GALACELA Phase 2 trial (NCT05856448) is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG3667 in adults with active SLE.
-
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
8/1/2023
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2023 and highlighted recent progress across its business.
-
Sapreme Appoints Experienced Industry Executives, Dr. Jeanne Bolger and Dr. Andre Hoekema, to its Board of Directors
7/20/2023
Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, announced the appointment of experienced biopharmaceutical industry executives Jeanne Bolger, MD, and Andre Hoekema, PhD, to its Board of Directors.
-
Bridge Biotherapeutics Joins PROLIFIC, the Prognostic Lung Fibrosis Consortium
7/11/2023
Bridge Biotherapeutics announced that it has joined PROLIFIC, the Prognostic Lung Fibrosis Consortium, an organization devoted to boosting scientific exploration and drug development in pulmonary fibrosis.
-
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
6/26/2023
uniQure N.V. today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately.
-
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
6/15/2023
Galapagos NV announced the appointment of Thad Huston as Chief Financial Officer and Chief Operating Officer as per 1 July 2023.
-
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
6/12/2023
Galapagos NV announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director.
-
MRM Health Appoints Katja Conrath as Chief Scientific Officer
6/7/2023
MRM Health - a clinical-stage biopharmaceutical company focused on developing innovative microbiome-based biotherapeutics based on its proprietary and unique CORAL® platform technology - announced that it appointed Katja Conrath, PhD, as Chief Scientific Officer.
-
Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress
6/5/2023
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will feature theCAR-T point-of-care manufacturing platform and will present previously disclosed initial Phase 1/2 data with CD19 CAR-T candidate, GLPG5201, at the European Hematology Association (EHA) 2023 congress, taking place from 8 June to 11June 2023 in Frankfurt, Germany.
-
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
5/23/2023
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was dosed in GALARISSO, the Phase 2 dermatomyositis (DM) trial with GLPG3667.
-
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
5/22/2023
Galapagos NV (Euronext & NASDAQ: GLPG) will present a broad range of abstracts, including analysis from randomized controlled trials (RCTs) and real-world evidence (RWE) studies at the European League Against Rheumatism (EULAR) annual congress taking place from 31 May to 3 June 2023 in Milan.
-
Galapagos creates new subscription right plans - May 05, 2023
5/5/2023
Galapagos NV announced that its Board of Directors created 1,975,000subscription rights under new subscription rightplans for the benefit of certain members ofthe personnelof the company and its subsidiaries.
-
Galapagos announces first quarter 2023 financial results
5/4/2023
Galapagos NV announced its first quarter 2023 financial results, a year-to-date business update and its outlook for the remainder of 2023.
-
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
5/2/2023
Galapagos NV announced the departure of Bart Filius, President, Chief Operating Officer and Chief Financial Officer.
-
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
4/26/2023
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was randomized inOLINGUITO, the pivotal Phase 3 program of filgotinib inAxSpA.Topline results are expected in H2 2025.
-
Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting
4/25/2023
Galapagos NV announces the approval of all resolutions proposed at its annual shareholders’ meeting held today at 14.00 CET.
-
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
4/18/2023
ProQR Therapeutics NV. announced the Annual General Meeting of Shareholders will take place on Wednesday, May 17, 2023 at 16:00 CET at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands.
-
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
4/12/2023
AIM ImmunoTech Inc. today announced the appointment of W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (“SAB").
-
Galapagos and NovAliX enter into an integrated drug discovery collaboration
3/30/2023
Galapagos NV (Euronext & NASDAQ: GLPG)and NovAliX today announced a strategic collaboration in which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred toNovAliX, a drug discovery-focused Contract Research Organization.
-
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
3/24/2023
Ryvu Therapeutics reported financial results for the fourth quarter and the full year ended December 31, 2022, and provided a corporate update.